Aratana Therapeutics, Inc. stock price

Aratana Therapeutics, Inc. latest news:


  • 12/15/2017 14:31:13

    BRIEF-Aratana Therapeutics Says Study Did Not Achieve Protocol-Defined Efficacy Success Criteria

    Aratana Therapeutics Inc(PETX): * ARATANA THERAPEUTICS ANNOUNCES STUDY RESULTS FOR AT-016. * Aratana Therapeutics Inc(PETX) - ARATANA'S LICENSE PARTNER RESPONSIBLE FOR DEVELOPMENT OF AT-016 SHARED RESULTS OF A PIVOTAL STUDY. * ARATANA THERAPEUTICS (PETX) - RECEIVED TOP-LINE PIVOTAL FIELD EFFECTIVENESS STUDY RESULTS FOR AT-016.

  • 11/28/2017 17:08:57

    Aratana cancels stock offering after shares plunge

    Aratana Therapeutics Inc. canceled plans for a stock offering Tuesday afternoon, one day after it announced the equity issuance and saw its share price plunge in response. The pet-medicine company said in a news release late Tuesday that it was canceling the offering because "current market conditions are not conducive for an offering." After announcing plans to sell at least $35 million in fresh shares Monday evening, Aratana stock plunged 19% in Tuesday's regular trading session to close at $5.86. The stock rebounded after the offering was canceled Tuesday, gaining more than 10% to hit $6.50 in after-hours trading.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Arbutus Biopharma CorporationABUS | ARC Group Worldwide, Inc.ARCW | ARCA biopharma, Inc.ABIO | Arcadia Biosciences, Inc.RKDA | ArcBest CorporationARCB | Arch Capital Group Ltd.ACGL | Arctic Cat Inc.ACAT | Ardelyx, Inc.ARDX | Arena Pharmaceuticals, Inc.ARNA | Ares Capital CorporationARCC |